50 research outputs found

    Antidepressant augmentation versus switch in treatment-resistant geriatric depression

    Get PDF
    BACKGROUND: The benefits and risks of augmenting or switching antidepressants in older adults with treatment-resistant depression have not been extensively studied. METHODS: We conducted a two-step, open-label trial involving adults 60 years of age or older with treatment-resistant depression. In step 1, patients were randomly assigned in a 1:1:1 ratio to augmentation of existing antidepressant medication with aripiprazole, augmentation with bupropion, or a switch from existing antidepressant medication to bupropion. Patients who did not benefit from or were ineligible for step 1 were randomly assigned in step 2 in a 1:1 ratio to augmentation with lithium or a switch to nortriptyline. Each step lasted approximately 10 weeks. The primary outcome was the change from baseline in psychological well-being, assessed with the National Institutes of Health Toolbox Positive Affect and General Life Satisfaction subscales (population mean, 50; higher scores indicate greater well-being). A secondary outcome was remission of depression. RESULTS: In step 1, a total of 619 patients were enrolled; 211 were assigned to aripiprazole augmentation, 206 to bupropion augmentation, and 202 to a switch to bupropion. Well-being scores improved by 4.83 points, 4.33 points, and 2.04 points, respectively. The difference between the aripiprazole-augmentation group and the switch-to-bupropion group was 2.79 points (95% CI, 0.56 to 5.02; P = 0.014, with a prespecified threshold P value of 0.017); the between-group differences were not significant for aripiprazole augmentation versus bupropion augmentation or for bupropion augmentation versus a switch to bupropion. Remission occurred in 28.9% of patients in the aripiprazole-augmentation group, 28.2% in the bupropion-augmentation group, and 19.3% in the switch-to-bupropion group. The rate of falls was highest with bupropion augmentation. In step 2, a total of 248 patients were enrolled; 127 were assigned to lithium augmentation and 121 to a switch to nortriptyline. Well-being scores improved by 3.17 points and 2.18 points, respectively (difference, 0.99; 95% CI, -1.92 to 3.91). Remission occurred in 18.9% of patients in the lithium-augmentation group and 21.5% in the switch-to-nortriptyline group; rates of falling were similar in the two groups. CONCLUSIONS: In older adults with treatment-resistant depression, augmentation of existing antidepressants with aripiprazole improved well-being significantly more over 10 weeks than a switch to bupropion and was associated with a numerically higher incidence of remission. Among patients in whom augmentation or a switch to bupropion failed, changes in well-being and the occurrence of remission with lithium augmentation or a switch to nortriptyline were similar. (Funded by the Patient-Centered Outcomes Research Institute; OPTIMUM ClinicalTrials.gov number, NCT02960763.)

    Genomics and transcriptomics yields a system-level view of the biology of the pathogen Naegleria fowleri

    Get PDF
    Background The opportunistic pathogen Naegleria fowleri establishes infection in the human brain, killing almost invariably within 2 weeks. The amoeba performs piece-meal ingestion, or trogocytosis, of brain material causing direct tissue damage and massive inflammation. The cellular basis distinguishing N. fowleri from other Naegleria species, which are all non-pathogenic, is not known. Yet, with the geographic range of N. fowleri advancing, potentially due to climate change, understanding how this pathogen invades and kills is both important and timely. Results Here, we report an -omics approach to understanding N. fowleri biology and infection at the system level. We sequenced two new strains of N. fowleri and performed a transcriptomic analysis of low- versus high-pathogenicity N. fowleri cultured in a mouse infection model. Comparative analysis provides an in-depth assessment of encoded protein complement between strains, finding high conservation. Molecular evolutionary analyses of multiple diverse cellular systems demonstrate that the N. fowleri genome encodes a similarly complete cellular repertoire to that found in free-living N. gruberi. From transcriptomics, neither stress responses nor traits conferred from lateral gene transfer are suggested as critical for pathogenicity. By contrast, cellular systems such as proteases, lysosomal machinery, and motility, together with metabolic reprogramming and novel N. fowleri proteins, are all implicated in facilitating pathogenicity within the host. Upregulation in mouse-passaged N. fowleri of genes associated with glutamate metabolism and ammonia transport suggests adaptation to available carbon sources in the central nervous system. Conclusions In-depth analysis of Naegleria genomes and transcriptomes provides a model of cellular systems involved in opportunistic pathogenicity, uncovering new angles to understanding the biology of a rare but highly fatal pathogen.publishedVersio

    Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population

    Get PDF
    The COVID-19 pandemic led to the rapid and worldwide development of highly effective vaccines against SARS-CoV-2. However, there is significant individual-to-individual variation in vaccine efficacy due to factors including viral variants, host age, immune status, environmental and host genetic factors. Understanding those determinants driving this variation may inform the development of more broadly protective vaccine strategies. While host genetic factors are known to impact vaccine efficacy for respiratory pathogens such as influenza and tuberculosis, the impact of host genetic variation on vaccine efficacy against COVID-19 is not well understood. To model the impact of host genetic variation on SARS-CoV-2 vaccine efficacy, while controlling for the impact of non-genetic factors, we used the Diversity Outbred (DO) mouse model. We found that DO mice immunized against SARS-CoV-2 exhibited high levels of variation in vaccine-induced neutralizing antibody responses. While the majority of the vaccinated mice were protected from virus-induced disease, similar to human populations, we observed vaccine breakthrough in a subset of mice. Importantly, we found that this variation in neutralizing antibody, virus-induced disease, and viral titer is heritable, indicating that the DO serves as a useful model system for studying the contribution of genetic variation of both vaccines and disease outcomes

    Sex Differences in a Network Model of Depressive Symptoms

    No full text
    Major Depressive Disorder (MDD) is one of the most prevalent mental health disorders, with a lifetime prevalence rate of 13-16% and 12-month prevalence rates of 5-7%. It has long been established that the rates of MDD in females is two to three times that of males. Previous research has examined sex differences in the occurrence and severity of MDD symptoms, primarily indicating greater severity of appetite increase and weight gain in females compared to males. The majority of previous research has been conducted assuming the latent factor model that MDD accounts for the symptoms of depression, and sex operates as a mediator or moderator between the latent variable and MDD, or between MDD and its symptoms. The present study used network analysis to examine whether there are sex differences in the relations between symptoms of depression, which might be an important factor for understanding sex differences in prevalence rates of MDD. The present study compared networks of DSM MDD symptoms between currently depressed females and males, and separate networks that also included other symptoms commonly associated with depression (e.g., anxiety, anger). Sex differences were examined using jointly estimated networks, and a Network Comparison Test (NCT) for the independently estimated networks. Results indicated no sex differences in depression symptom networks. These results indicate that depressive symptom networks, or the relations between symptoms are not an important factor for understanding the disparity in sex differences in MDD prevalence rates. Interestingly, non-DSM symptoms were among the strongest and most important symptoms within the network, suggesting future research and diagnostic criteria should consider inclusion of non-DSM symptoms associated with MDD

    Engagement in health and wellness: An online incentive-based program

    No full text
    Increasingly, corporate health promotion programs are implementing wellness programs integrating principles of behavioral economics. Employees of a large firm were provided a customized online incentive program to design their own commitments to meet health goals. This study examines patterns of program participation and engagement in health promotion activities. Subjects were US-based employees of a large, nondurable goods manufacturing firm who were enrolled in corporate health benefits in 2010 and 2011. We assessed measures of engagement with the workplace health promotion program (e.g., incentive points earned, weight loss). To further examine behaviors indicating engagement in health promotion activities, we constructed an aggregate, employee-level engagement index. Regression models were employed to assess the association between employee characteristics and the engagement index, and the engagement index and spending. 4220 employees utilized the online program and made 25,716 commitments. Male employees age 18–34 had the highest level of engagement, and male employees age 55–64 had the lowest level of engagement overall. Prior year health status and prior year spending did not show a significant association with the level of engagement with the program (p > 0.05). Flexible, incentive-based behavioral health and lifestyle programs may reach the broader workforce including those with chronic conditions and higher levels of health spending

    Genes of interest from previous studies.

    No full text
    *<p>Expression ratio: parasitic/saprobic expression. Ratios >1.0 indicate higher expression (up-regulation) in the parasitic phase and ratios <1.0 indicate higher expression (up-regulation) in the saprobic phase.</p>**<p>p-value <0.05.</p

    <i>Coccidioides</i> growth cycle and study overview.

    No full text
    <p><i>Coccidioides</i> growth cycle in culture (<b>A</b>), total RNA was collected at 96 hours from hyphae and spherules, which were grown at 30°C and 39°C, respectively. Lifecycle in culture illustration adapted from Delgado <i>et al</i>, 2003 <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0041034#pone.0041034-Delgado1" target="_blank">[11]</a>. Samples were collected in biological triplicate and the results from <i>C. immitis</i> isolate RS and <i>C. posadasii</i> isolate C735 were compared (<b>B</b>).</p

    Differentially expressed genes in <i>C. immitis</i> and <i>C. posadasii</i>.

    No full text
    <p>Venn diagrams showing the number of genes commonly differentially regulated in the saprobic vs. parasitic growth phases of <i>C. immitis</i> and <i>C. posadasii</i>.</p
    corecore